Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Shares Sold by Pacer Advisors Inc.

Pacer Advisors Inc. cut its stake in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) by 4.4% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund owned 20,055 shares of the biotechnology company’s stock after selling 932 shares during the period. Pacer Advisors Inc.’s holdings in Sarepta Therapeutics were worth $2,438,000 as of its most recent SEC filing.

A number of other institutional investors have also recently bought and sold shares of SRPT. MassMutual Private Wealth & Trust FSB boosted its holdings in shares of Sarepta Therapeutics by 169.6% in the 4th quarter. MassMutual Private Wealth & Trust FSB now owns 248 shares of the biotechnology company’s stock valued at $30,000 after purchasing an additional 156 shares during the last quarter. Sunbelt Securities Inc. raised its position in shares of Sarepta Therapeutics by 446.2% in the 3rd quarter. Sunbelt Securities Inc. now owns 284 shares of the biotechnology company’s stock worth $35,000 after buying an additional 232 shares during the period. Huntington National Bank boosted its holdings in Sarepta Therapeutics by 150.9% in the third quarter. Huntington National Bank now owns 291 shares of the biotechnology company’s stock valued at $36,000 after acquiring an additional 175 shares during the last quarter. UMB Bank n.a. grew its position in Sarepta Therapeutics by 105.9% during the third quarter. UMB Bank n.a. now owns 383 shares of the biotechnology company’s stock valued at $48,000 after acquiring an additional 197 shares during the period. Finally, Values First Advisors Inc. acquired a new stake in Sarepta Therapeutics during the third quarter worth about $59,000. 86.68% of the stock is currently owned by hedge funds and other institutional investors.

Sarepta Therapeutics Stock Performance

Shares of Sarepta Therapeutics stock opened at $113.72 on Friday. The firm has a market cap of $10.86 billion, a PE ratio of 90.98 and a beta of 0.77. Sarepta Therapeutics, Inc. has a 1 year low of $102.15 and a 1 year high of $173.25. The firm’s 50-day simple moving average is $122.80 and its 200-day simple moving average is $127.23. The company has a debt-to-equity ratio of 0.93, a quick ratio of 3.03 and a current ratio of 3.84.

Insider Buying and Selling at Sarepta Therapeutics

In related news, Director Kathryn Jean Boor sold 1,636 shares of the firm’s stock in a transaction on Thursday, December 5th. The stock was sold at an average price of $125.55, for a total transaction of $205,399.80. Following the transaction, the director now directly owns 5,880 shares in the company, valued at $738,234. This trade represents a 21.77 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Hans Lennart Rudolf Wigzell sold 10,500 shares of Sarepta Therapeutics stock in a transaction on Thursday, December 12th. The stock was sold at an average price of $124.84, for a total transaction of $1,310,820.00. Following the completion of the transaction, the director now directly owns 22,840 shares of the company’s stock, valued at approximately $2,851,345.60. This represents a 31.49 % decrease in their position. The disclosure for this sale can be found here. 7.70% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

Several equities analysts have recently weighed in on SRPT shares. Guggenheim lifted their price objective on Sarepta Therapeutics from $148.00 to $150.00 and gave the company a “buy” rating in a research note on Thursday, November 7th. Royal Bank of Canada reaffirmed an “outperform” rating and set a $182.00 price target on shares of Sarepta Therapeutics in a research report on Monday, October 21st. StockNews.com lowered shares of Sarepta Therapeutics from a “buy” rating to a “hold” rating in a research report on Wednesday, November 20th. Cantor Fitzgerald upgraded shares of Sarepta Therapeutics from a “neutral” rating to an “overweight” rating and lifted their target price for the company from $152.00 to $167.00 in a report on Thursday, November 7th. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $202.00 price target on shares of Sarepta Therapeutics in a report on Monday, January 27th. One analyst has rated the stock with a sell rating, two have given a hold rating, nineteen have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat, Sarepta Therapeutics currently has an average rating of “Moderate Buy” and a consensus price target of $178.71.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.